{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-032182","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.562175+00:00","generated_at":"2026-05-31T19:47:06.642326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance","bullets":["GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).","FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.","Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).","New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).","Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-032182","json":"https://secwatch.observer/filing/0001628280-24-032182.json","markdown":"https://secwatch.observer/filing/0001628280-24-032182.md","text":"https://secwatch.observer/filing/0001628280-24-032182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/0001628280-24-032182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/abt-20240718.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:47:06.642326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}